These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2213 related articles for article (PubMed ID: 9613910)

  • 1. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin.
    Downs JR; Clearfield M; Tyroler HA; Whitney EJ; Kruyer W; Langendorfer A; Zagrebelsky V; Weis S; Shapiro DR; Beere PA; Gotto AM
    Am J Cardiol; 2001 May; 87(9):1074-9. PubMed ID: 11348605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women.
    Clearfield M; Downs JR; Weis S; Whitney EJ; Kruyer W; Shapiro DR; Stein EA; Langendorfer A; Beere PA; Gotto AM
    J Womens Health Gend Based Med; 2001 Dec; 10(10):971-81. PubMed ID: 11788107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Downs JR; Beere PA; Whitney E; Clearfield M; Weis S; Rochen J; Stein EA; Shapiro DR; Langendorfer A; Gotto AM
    Am J Cardiol; 1997 Aug; 80(3):287-93. PubMed ID: 9264420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population.
    Clearfield M; Whitney EJ; Weis S; Downs JR; Shapiro DR; Stein EA; Watson DJ; Langendörfer A; Beere PA; Stamler J; Gotto AM
    J Cardiovasc Risk; 2000 Apr; 7(2):125-33. PubMed ID: 10879416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing the benefit of statins in low-to-moderate--risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Gotto AM
    Atheroscler Suppl; 2007 Aug; 8(2):3-8. PubMed ID: 17588826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Gotto AM; Whitney E; Stein EA; Shapiro DR; Clearfield M; Weis S; Jou JY; Langendörfer A; Beere PA; Watson DJ; Downs JR; de Cani JS
    Circulation; 2000 Feb; 101(5):477-84. PubMed ID: 10662743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
    Clearfield MB; Weis SE; Willis JM; Vasenius KA; McConathy WJ
    J Am Osteopath Assoc; 2002 Jul; 102(7):377-84. PubMed ID: 12138952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights on treating an over-the-counter-type subgroup: data from the Air Force/Texas Coronary Atherosclerosis Prevention Study Population.
    Gotto AM
    Am J Cardiol; 2000 Jun; 85(12A):8E-14E. PubMed ID: 10858488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
    Athyros VG; Papageorgiou AA; Mercouris BR; Athyrou VV; Symeonidis AN; Basayannis EO; Demitriadis DS; Kontopoulos AG
    Curr Med Res Opin; 2002; 18(4):220-8. PubMed ID: 12201623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines.
    Clearfield M; Downs JR; Lee M; Langendorfer A; McConathy W; Gotto AM
    Am J Cardiol; 2005 Dec; 96(12):1674-80. PubMed ID: 16360356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
    Cui Y; Watson DJ; Girman CJ; Shapiro DR; Gotto AM; Hiserote P; Clearfield MB
    Am J Cardiol; 2009 Sep; 104(6):829-34. PubMed ID: 19733719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).
    Pyŏrälä K; Pedersen TR; Kjekshus J; Faergeman O; Olsson AG; Thorgeirsson G
    Diabetes Care; 1997 Apr; 20(4):614-20. PubMed ID: 9096989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.
    Ballantyne CM; Olsson AG; Cook TJ; Mercuri MF; Pedersen TR; Kjekshus J
    Circulation; 2001 Dec; 104(25):3046-51. PubMed ID: 11748098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
    Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
    JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.
    Boden WE
    Am J Cardiol; 2000 Dec; 86(12A):19L-22L. PubMed ID: 11374850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events.
    Ridker PM; Shih J; Cook TJ; Clearfield M; Downs JR; Pradhan AD; Weis SE; Gotto AM;
    Circulation; 2002 Apr; 105(15):1776-9. PubMed ID: 11956118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 111.